NXEN OTC
Nexien BioPharma, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -99.2%
3Y: -99.8%
5Y: -99.9%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$156K
+44.9% ▲
Net Income
-$239K
+34.0% ▲
EPS (Diluted)
$-0.00
+37.9% ▲
EBITDA
-$337
+44.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3M | $2M | $454K | $283K | $156K |
| Operating Expenses | $3M | $2M | $341K | $283K | $156K |
| Operating Income | -$3M | -$750K | -$341K | -$283K | -$156K |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $33 | $16K | $62K | $79K | $83K |
| Income Before Tax | -$3M | -$2M | -$626K | -$362K | -$239K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$3M | -$2M | -$626K | -$362K | -$239K |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.05 | $-0.03 | $-0.01 | $-0.01 | $-0.00 |
| EBITDA | -$3M | $0 | -$454K | -$392 | -$337 |
| Shares Outstanding | 54M | 55M | 58M | 62M | 66M |